Summary
25.12 0.19(0.74%)05/16/2024
Insmed Inc (INSM)
Insmed Inc (INSM)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.48 | 5.52 | -7.24 | -10.02 | 6.86 | 37.96 | -7.73 | -84.20 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 26.08 | |
| Open | 26.15 | |
| High | 26.22 | |
| Low | 25.61 | |
| Volume | 879,358 | |
| Change | 0.13 | |
| Change % | 0.48 | |
| Avg Volume (20 Days) | 1,593,117 | |
| Volume/Avg Volume (20 Days) Ratio | 0.55 | |
| 52 Week Range | 18.09 - 32.00 | |
| Price vs 52 Week High | -18.52% | |
| Price vs 52 Week Low | 44.14% | |
| Range | -0.29 | |
| Gap Up/Down | -0.06 | |
Fundamentals | ||
| Market Capitalization (Mln) | 3,696 | |
| EBIDTA | -671,894,976 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 44.56 | |
| Book Value | -3.1290 | |
| Earnings Per Share | -5.3400 | |
| EPS Estimate Current Quarter | -1.2300 | |
| EPS Estimate Next Quarter | -1.1400 | |
| EPS Estimate Current Year | -4.5800 | |
| EPS Estimate Next Year | -3.7500 | |
| Diluted EPS (TTM) | -5.3400 | |
| Revenues | ||
| Profit Marging | -2.3674 | |
| Operating Marging (TTM) | -2.0848 | |
| Return on asset (TTM) | -0.3179 | |
| Return on equity (TTM) | -14.5341 | |
| Revenue TTM | 315,494,016 | |
| Revenue per share TTM | 2.1990 | |
| Quarterly Revenue Growth (YOY) | 0.1580 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 190,232,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 25.4507 | |
| Revenue Enterprise Value | 14.6561 | |
| EBITDA Enterprise Value | -6.7757 | |
| Shares | ||
| Shares Outstanding | 148,604,992 | |
| Shares Float | 147,201,721 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.06 | |
| Insider (%) | 1.09 | |
| Institutions (%) | 105.04 | |
05/10 12:15 EST - zacks.com
Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates
Insmed (INSM) Q1 earnings beat estimates while sales miss the mark. Management posts positive data readouts from mid-stage studies on its experimental inhalation powder in PH-ILD and PAH indications.
Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates
Insmed (INSM) Q1 earnings beat estimates while sales miss the mark. Management posts positive data readouts from mid-stage studies on its experimental inhalation powder in PH-ILD and PAH indications.
05/09 16:29 EST - seekingalpha.com
Insmed, Inc. (INSM) Q1 2024 Earnings Call Transcript
Insmed, Inc. (NASDAQ:INSM ) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants Bryan Dunn - Executive Director, Investor Relations William Lewis - Chairman, President & CEO Eugene Sullivan - Chief Product Strategy Officer & Chief Scientific Officer Sara Bonstein - CFO Conference Call Participants Andrea Tan - Goldman Sachs & Co. Jessica Fye - JPMorgan Securities Leon Wang - Barclays Capital Joseph Schwartz - Leerink Partners Nicole Germino - Truist Securities Jason Zemansky - Bank of America Merrill Lynch Ritu Baral - Cowen & Co. Jeff Hung - Morgan Stanley Liisa Bayko - Evercore ISI Jennifer Kim - Cantor Fitzgerald Stephen Willey - Stifel Operator Thank you for standing by. My name is Dee, and I will be your conference operator today.
Insmed, Inc. (INSM) Q1 2024 Earnings Call Transcript
Insmed, Inc. (NASDAQ:INSM ) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants Bryan Dunn - Executive Director, Investor Relations William Lewis - Chairman, President & CEO Eugene Sullivan - Chief Product Strategy Officer & Chief Scientific Officer Sara Bonstein - CFO Conference Call Participants Andrea Tan - Goldman Sachs & Co. Jessica Fye - JPMorgan Securities Leon Wang - Barclays Capital Joseph Schwartz - Leerink Partners Nicole Germino - Truist Securities Jason Zemansky - Bank of America Merrill Lynch Ritu Baral - Cowen & Co. Jeff Hung - Morgan Stanley Liisa Bayko - Evercore ISI Jennifer Kim - Cantor Fitzgerald Stephen Willey - Stifel Operator Thank you for standing by. My name is Dee, and I will be your conference operator today.
05/09 11:01 EST - zacks.com
Insmed (INSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Insmed (INSM) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Insmed (INSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Insmed (INSM) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
05/09 09:16 EST - zacks.com
Insmed (INSM) Reports Q1 Loss, Lags Revenue Estimates
Insmed (INSM) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to loss of $1.17 per share a year ago.
Insmed (INSM) Reports Q1 Loss, Lags Revenue Estimates
Insmed (INSM) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to loss of $1.17 per share a year ago.
05/09 07:00 EST - prnewswire.com
Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update
— ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $75.5 Million for the First Quarter of 2024, Reflecting 16% Annual Growth Over the First Quarter of 2023— —Company Reports Positive Topline Safety and Tolerability Data from the Phase 2 PH-ILD Study of TPIP with 79.3% of Patients Reaching the Maximum Dose of 640 µg by Week 5, with an Unexpectedly Positive and Robust Signal on the Exploratory Endpoint of Clinical Worsening— —Encouraging Blinded Data from First 40 Patients in Phase 2 PAH Study of TPIP, with Combined Active Treatment and Placebo Arms Showing Mean PVR Reduction of 19.9% and 6-Minute Walk Distance Improvement of 43 Meters— —Topline Data from the Phase 3 ASPEN Trial of Brensocatib in Patients with Bronchiectasis Remains on Track to Read Out in the Latter Part of Second-Quarter 2024— —Company Reiterates 2024 Global ARIKAYCE Revenue Guidance in the Range of $340 Million to $360 Million, Reflecting Double-Digit Growth Compared to 2023— BRIDGEWATER, N.J. , May 9, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.
Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update
— ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $75.5 Million for the First Quarter of 2024, Reflecting 16% Annual Growth Over the First Quarter of 2023— —Company Reports Positive Topline Safety and Tolerability Data from the Phase 2 PH-ILD Study of TPIP with 79.3% of Patients Reaching the Maximum Dose of 640 µg by Week 5, with an Unexpectedly Positive and Robust Signal on the Exploratory Endpoint of Clinical Worsening— —Encouraging Blinded Data from First 40 Patients in Phase 2 PAH Study of TPIP, with Combined Active Treatment and Placebo Arms Showing Mean PVR Reduction of 19.9% and 6-Minute Walk Distance Improvement of 43 Meters— —Topline Data from the Phase 3 ASPEN Trial of Brensocatib in Patients with Bronchiectasis Remains on Track to Read Out in the Latter Part of Second-Quarter 2024— —Company Reiterates 2024 Global ARIKAYCE Revenue Guidance in the Range of $340 Million to $360 Million, Reflecting Double-Digit Growth Compared to 2023— BRIDGEWATER, N.J. , May 9, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.
05/08 11:21 EST - zacks.com
Should You Buy Insmed (INSM) Ahead of Earnings?
Insmed (INSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Should You Buy Insmed (INSM) Ahead of Earnings?
Insmed (INSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
05/07 08:00 EST - prnewswire.com
Insmed To Present at the BofA Securities Health Care Conference 2024
BRIDGEWATER, N.J. , May 7, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the BofA Securities Health Care Conference 2024 in Las Vegas, NV, on Tuesday, May 14, 2024 at 2:20 p.m.
Insmed To Present at the BofA Securities Health Care Conference 2024
BRIDGEWATER, N.J. , May 7, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the BofA Securities Health Care Conference 2024 in Las Vegas, NV, on Tuesday, May 14, 2024 at 2:20 p.m.
05/03 08:00 EST - prnewswire.com
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J. , May 3, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 63 new employees.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J. , May 3, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 63 new employees.
05/02 11:06 EST - zacks.com
Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/25 08:00 EST - prnewswire.com
Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024
BRIDGEWATER, N.J. , April 25, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first-quarter 2024 financial results on Thursday, May 9, 2024.
Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024
BRIDGEWATER, N.J. , April 25, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first-quarter 2024 financial results on Thursday, May 9, 2024.
03/27 16:05 EST - prnewswire.com
Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference
—Additional Data from ARISE Study Evaluating the Impact of ARIKAYCE on Microbiologic Outcomes in Patients with Newly Diagnosed or Recurrent MAC Lung Disease to be Presented as Late-Breaker— —Data to be Presented from ARISE Examining Change in Patient-Reported Respiratory Symptoms— BRIDGEWATER, N.J. , March 27, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will present nine abstracts from across its respiratory portfolio at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego.
Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference
—Additional Data from ARISE Study Evaluating the Impact of ARIKAYCE on Microbiologic Outcomes in Patients with Newly Diagnosed or Recurrent MAC Lung Disease to be Presented as Late-Breaker— —Data to be Presented from ARISE Examining Change in Patient-Reported Respiratory Symptoms— BRIDGEWATER, N.J. , March 27, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will present nine abstracts from across its respiratory portfolio at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego.
02/29 08:00 EST - prnewswire.com
Insmed To Present at Three March Conferences
BRIDGEWATER, N.J. , Feb. 29, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor conferences: The TD Cowen 44th Annual Health Care Conference in Boston on Monday, March 4, 2024, at 2:50 p.m.
Insmed To Present at Three March Conferences
BRIDGEWATER, N.J. , Feb. 29, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor conferences: The TD Cowen 44th Annual Health Care Conference in Boston on Monday, March 4, 2024, at 2:50 p.m.
02/22 13:00 EST - seekingalpha.com
Insmed Incorporated (INSM) Q4 2023 Earnings Call Transcript
Insmed Incorporated (INSM) Q4 2023 Earnings Call Transcript
Insmed Incorporated (INSM) Q4 2023 Earnings Call Transcript
Insmed Incorporated (INSM) Q4 2023 Earnings Call Transcript
02/22 09:10 EST - zacks.com
Insmed (INSM) Reports Q4 Loss, Misses Revenue Estimates
Insmed (INSM) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.20 per share a year ago.
Insmed (INSM) Reports Q4 Loss, Misses Revenue Estimates
Insmed (INSM) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.20 per share a year ago.
02/22 07:00 EST - prnewswire.com
Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update
—Topline Data from the Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis Remain on Track to Read Out in the Latter Part of Second-Quarter 2024— —Enrollment in the Phase 2 Study of TPIP in Patients with PH-ILD Completed in November 2023; Topline Data Expected in Second-Quarter 2024 Ahead of the ASPEN Readout— —Company Ends 2023 With $780 Million of Cash, Cash Equivalents, and Marketable Securities, Providing Runway Beyond the Expected ASPEN Readout— — ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $83.7 Million for Fourth-Quarter and $305.2 Million for Full-Year 2023, Reflecting 24% Annual Growth and Exceeding the Upper End of Full-Year 2023 Guidance Range— —Company Reiterates Sales Guidance for 2024 Global ARIKAYCE Revenues in the Range of $340 Million to $360 Million, Reflecting Double-Digit Growth Compared to 2023— BRIDGEWATER, N.J. , Feb. 22, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.
Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update
—Topline Data from the Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis Remain on Track to Read Out in the Latter Part of Second-Quarter 2024— —Enrollment in the Phase 2 Study of TPIP in Patients with PH-ILD Completed in November 2023; Topline Data Expected in Second-Quarter 2024 Ahead of the ASPEN Readout— —Company Ends 2023 With $780 Million of Cash, Cash Equivalents, and Marketable Securities, Providing Runway Beyond the Expected ASPEN Readout— — ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $83.7 Million for Fourth-Quarter and $305.2 Million for Full-Year 2023, Reflecting 24% Annual Growth and Exceeding the Upper End of Full-Year 2023 Guidance Range— —Company Reiterates Sales Guidance for 2024 Global ARIKAYCE Revenues in the Range of $340 Million to $360 Million, Reflecting Double-Digit Growth Compared to 2023— BRIDGEWATER, N.J. , Feb. 22, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.
02/08 08:00 EST - prnewswire.com
Insmed to Host Fourth-Quarter and Full Year 2023 Financial Results Conference Call on Thursday, February 22, 2024
BRIDGEWATER, N.J. , Feb. 8, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its fourth-quarter and full year 2023 financial results on Thursday, February 22, 2024.
Insmed to Host Fourth-Quarter and Full Year 2023 Financial Results Conference Call on Thursday, February 22, 2024
BRIDGEWATER, N.J. , Feb. 8, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its fourth-quarter and full year 2023 financial results on Thursday, February 22, 2024.